FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:38-47 January 4, 2001 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Editorial by Hale, R. W. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Misoprostol is a prostaglandin E₁ analogue that has been approved by the Food and Drug Administration (FDA) to be taken orally for the prevention and treatment of gastric ulcers associated with the use of nonsteroidal antiinflammatory drugs. It has also become an important drug in obstetrical and gynecologic practice because of its uterotonic and cervical-ripening actions. Misoprostol is useful for elective medical abortion, cervical ripening before surgical abortion, evacuation of the uterus in cases of embryonic or fetal death, and induction of labor. The drug may also be used to treat and even prevent postpartum hemorrhage. However, misoprostol is not . . . [Full Text of this Article]

Pharmacokinetics, Physiology, and Teratogenicity

Misoprostol in the First Trimester of Pregnancy

Medical Abortion

Failed Pregnancy or Fetal Death

Cervical Ripening before Surgical Abortion

Misoprostol in the Second Trimester of Pregnancy

Abortion

Misoprostol in the Third Trimester of Pregnancy

Induction of Labor with a Viable Fetus

Induction of Labor after Fetal Death

Induction of Labor in Women with Previous Cesarean Delivery

Misoprostol for Postpartum Hemorrhage

Conclusions

Source Information

From the Department of Obstetrics, Gynecology, and Reproductive Sciences, Center for Reproductive Health Research and Policy, San Francisco General Hospital and the University of California, San Francisco.

Address reprint requests to Dr. Goldberg at the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco General Hospital, 1001 Potrero Ave. Ward 6D-11, San Francisco, CA 94110.

References

This article has been cited by other articles:

• Bos-Thompson, M.-A., Hillaire-Buys, D., Roux, C., Faillie, J.-L., Amram, D. (2008). Mobius Syndrome in a Neonate After Mifepristone and Misoprostol Elective Abortion Failure. The Annals of Pharmacotherapy 42: 888-892 [Abstract] [Full Text]  
• Aronsson, A., Fiala, C., Stephansson, O., Granath, F., Watzer, B., Schweer, H., Gemzell-Danielsson, K. (2007). Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol. Hum Reprod 22: 1912-1918 [Abstract] [Full Text]  
• Winikoff, B. (2005). Pregnancy Failure and Misoprostol -- Time for a Change. NEJM 353: 834-836 [Full Text]  
• Graziosi, G.C.M., van der Steeg, J.W., Reuwer, P.H.W., Drogtrop, A.P., Bruinse, H.W., Mol, B.W.J. (2005). Economic evaluation of misoprostol in the treatment of early pregnancy failure compared to curettage after an expectant management. Hum Reprod 20: 1067-1071 [Abstract] [Full Text]  
• Chen, A., Yuan, W., Meirik, O., Wang, X., Wu, S.-Z., Zhou, L., Luo, L., Gao, E., Cheng, Y. (2004). Mifepristone-induced Early Abortion and Outcome of Subsequent Wanted Pregnancy. Am J Epidemiol 160: 110-117 [Abstract] [Full Text]  
• El-Refaey, H., Rodeck, C. (2003). Post-partum haemorrhage: definitions, medical and surgical management. A time for change. Br Med Bull 67: 205-217 [Abstract] [Full Text]  
• Verzijl, H. T.F.M., van der Zwaag, B., Cruysberg, J. R.M., Padberg, G. W. (2003). Mobius syndrome redefined: A syndrome of rhombencephalic maldevelopment. Neurology 61: 327-333 [Abstract] [Full Text]  
• van der Zwaag, B, Verzijl, H T F M, Beltran-Valero de Bernabe, D, Schuster, V L, van Bokhoven, H, Kremer, H, van Reen, M, Wichers, G H, Brunner, H G, Padberg, G W (2002). Mutation analysis in the candidate Mobius syndrome genes PGT and GATA2 on chromosome 3 and EGR2 on chromosome 10. J. Med. Genet. 39: e30-30 [Full Text]  
• Lowenstein, E., Wanzer, S. H. (2002). The U.S. Attorney General's Intrusion into Medical Practice. NEJM 346: 447-448 [Full Text]  
• Pang, M.W., Lee, T.S., Chung, T.K.H. (2001). Incomplete miscarriage: a randomized controlled trial comparing oral with vaginal misoprostol for medical evacuation. Hum Reprod 16: 2283-2287 [Abstract] [Full Text]  
• Gebhardt, D O E (2001). Misoprostol in a topsyturvy world. J. Med. Ethics 27: 205-205 [Full Text]  
• (2001). Recommendations for Use of Misoprostol in Pregnant Women. JWatch Women's Health 2001: 1-1 [Full Text]  
• Hale, R. W., Zinberg, S. (2001). Use of Misoprostol in Pregnancy. NEJM 344: 59-60 [Full Text]  
• Friedman, M. A. (2001). Manufacturer's Warning Regarding Unapproved Uses of Misoprostol. NEJM 344: 61-61 [Full Text]